Jason Bacharach, MD
Glaucoma Specialist · Petaluma, CANPI 1639160112
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AbbVie at 39.5% of the total. Among glaucoma specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,061 payments — averaging $803.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$654K
- Bausch & Lomb Americas Inc.$187K
- Alcon$133K
- Aerie Pharmaceuticals, Inc.$131K
- Sun Pharmaceutical Industries Inc.$120K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$100K
- plus $331K from 30 others
Across 316 payments — averaging $2548.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$183K
- Ocular Therapeutix, Inc.$112K
- AbbVie$107K
- Oyster Point Pharma, Inc.$87K
- Novartis$49K
- Aerie Pharmaceuticals, Inc.$44K
- plus $224K from 14 others
What the payments were for
- Consulting fees$574,36835%
- Speaking & faculty fees$922,72256%
- Travel & lodging$117,6267%
- Food & beverage$40,2712%
- Education$1050%
- Gifts$640%
- Other$2930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$415,068
- Rocklatan$223,897
- Rhopressa$208,903
- VYZULTA$188,028
- CEQUA$115,086
- LUMIGAN$84,169
- MIEBO$66,967
- OMNI(R) SURGICAL SYSTEM (US)$64,025
- COMBIGAN$53,736
- VUITY$53,426
- XIIDRA$45,927
- IYUZEH$39,874
- iDose$34,479
- SIMBRINZA$33,368
- DEXYCU$33,086
- RESTASIS$31,169
- TRAVATAN Z$17,528
- TRYPTYR$16,402
- iStent infinite Trabecular Micro-Bypass System Model iS3$14,000
- Travoprost Intraocular Implant - iDose$13,467
How this compares
$1,655,449 in reported general payments places this provider in the 95th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 620 | $388,266 |
| VyzultaLatanoprostene Bunod | 246 | $137,212 |
| RocklatanNetarsudil Mesylat/Latanoprost | 167 | $133,556 |
| RhopressaNetarsudil Mesylate | 111 | $75,837 |
| XiidraLifitegrast | 36 | $60,393 |
| CombiganBrimonidine Tartrate/Timolol | 121 | $58,859 |
| RestasisCyclosporine | 46 | $54,756 |
| MieboPerfluorohexyloctane/Pf | 25 | $29,006 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 58 | $28,620 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 130 | $28,527 |
| Alphagan PBrimonidine Tartrate | 44 | $25,329 |
| Brinzolamide | 65 | $14,690 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 78 | $14,204 |
| Travoprost | 77 | $12,566 |
| Timolol MaleateTimolol Maleate/Pf | 31 | $11,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $653,596 | $527,210831 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $187,487 | $226,610307 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $130,949 | $209,393278 claims |
| AlconSimbrinza, Azopt | $132,761 | $36,24769 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $99,572 | $13,42656 claims |
| NovartisTravatan Z | $19,160 | $6,03711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Petaluma
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
- Philip NgaiWest Covina$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.